Welcome to Cosmo Pharmaceuticals

Cosmo is a speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn’s Disease, as well as for colon infections and selected topically treated Skin Disorders.

Information for remaining BioXell Shareholders - click here for more


Product Pipeline

The company is developing a range
of drug projects that are mostly based
on its Multi Matrix MMX® technology.

Therapeutic Focus

Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders leading to the damage of the gastro-intestinal tract. The main forms of IBD are Ulcerative Colitis and Crohn’s Disease. Both diseases are clinically similar and may be described as a faulty regulation of the mucosal immune response.

Business Fields

Cosmo is engaged in two distinct fields:

  • Development and commercialisation of proprietary drugs, primarily focused on the treatment of Inflammatory Bowel Diseases and colon infections.
  • Manufacturing of pharmaceutical products for third parties and the provision of related services.

Share Price Ticker

Price17.00
Date30/07/2010
Time17:31 CEST 
Change1.00
Market capCHF 254.9 mln
Data is delayed by approximately 20 minutes

 

Upcoming Events

Latest News